Safety and Efficacy of VP-102, a Proprietary, Drug-Device Combination Product Containing Cantharidin, 0.7% (w/v), in Children and Adults With Molluscum Contagiosum: Two Phase 3 Randomized Clinical Trials

In 2 identical trials (n=582), topical application of cantharidin, an extract from blister beetles, every 21 days for a maximum of 4 treatments resulted in higher rates of complete lesion clearance compared to vehicle (46.3% vs. 18% and 54.0% vs. 13%, respectively).

Source:

JAMA Dermatology